Assessment of Pegagen tolerance and efficiency during the first line chemotherapy in patients with breast cancer during line chemotherapy in the 1396-1397

Authors:

Name and email: Arash Jelabi, arash_jenabian@yahoo.com

Address (Electronic):

Name and email: Masoumeh Khojeh, dr.mahsa73@gmail.com

Address (Physical):

President of the Pharmaceutical Sciences and Chemistry Research Center of Tehran University of Medical Sciences, and Institute of Pharmaceutical Sciences, and Chemistry Research Center Leader of the research, Dr. Saeed Anbari

Dean of Pharmaceutical Sciences and Chemistry Research Center of Tehran University of Medical Sciences, and Institute of Pharmaceutical Sciences, and Chemistry Research Center, Dr. Reza Shater

Dean of Pharmaceutical Sciences and Chemistry Research Center of Tehran University of Medical Sciences, and Institute of Pharmaceutical Sciences, and Chemistry Research Center, Dr. Reza Shater

Environments and Factors:

1. Efficiency of Pegagen administration in the first-line chemotherapy of breast cancer patients in the 1396-1397

2. Tolerance of Pegagen in the first-line chemotherapy of breast cancer patients in the 1396-1397

Methods:

1. The Pegagen tolerance and efficiency of breast cancer patients treated with first-line chemotherapy in the 1396-1397 were evaluated.

2. The results showed that Pegagen had good tolerance and efficiency in the first-line chemotherapy of breast cancer patients in the 1396-1397.

Conclusions:

1. Pegagen administration in the first-line chemotherapy of breast cancer patients is safe and effective in the 1396-1397.

2. Further studies are recommended to evaluate the long-term effects of Pegagen in the treatment of breast cancer patients.